As of Wednesday close, Supernus Pharmaceuticals Inc.’s (NASDAQ:SUPN) stock was down -$0.09, moving down -0.26 percent to $34.84. The average number of shares traded per day over the past five days has been 208,360 shares. 4 times new highs have been achieved over the past 5 days, with a $1.12 gain in that time frame. In the last twenty days, the average volume was 379,570, while in the previous 50 days, it was 403,552.
Since last month, SUPN stock rose 1.69%. Shares of the company fell to $31.92 on 11/09/22, the lowest level in the past month. A 52-week high of $36.08 was reached on 08/22/22 after having rallying from a 52-week low of $24.95. Since the beginning of this year, SUPN’s stock price has risen by 19.48% or $5.68, and marked a new high 13 times. However, the stock has declined by -3.44% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
SUPN stock investors should be aware that Supernus Pharmaceuticals Inc. (SUPN) stock had its last reported insider trading activity 2 days ago on Nov 22. Khattar Jack A., the President, CEO of the company, disposed of 600 shares for $35.00 on Nov 22. It resulted in a $21,001 divestment by the insider. Khattar Jack A. sold 531 shares at an average price of $35.01 on Nov 21. The insider now owns 781,059 shares following the transaction. On Nov 15, President, CEO Khattar Jack A. sold 1,115 shares at $35.00 apiece. The transaction was valued at $39,028.
Right now, Supernus Pharmaceuticals Inc. (SUPN) has a P/E ratio of about 56.01. The stock’s beta is 0.95. Besides these, the trailing price-to-sales (P/S) ratio of 2.82, the price-to-book (PB) ratio of 2.20, and the price-to-cash flow ratio of 13.52 may also be considered.
In the three months ended June 29, Supernus Pharmaceuticals Inc.’s quick ratio stood at 0.80, while its current ratio was 0.90, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 87.70% percent. In the year ended June 29, operating margins totaled 2.70%. Based on annual data, SUPN earned $504.71 million in gross profit and brought in $579.77 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 5.50%. Return on equity (ROE) for the past 12 months was 4.50%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SUPN’s revenue rose 16.29% during the quarter, while net income inched up to $177.35 million. While analysts expected Supernus Pharmaceuticals Inc. to report $0.29 quarterly earnings, the actual figure was $0.56 per share, beating the consensus estimate by 93.10%. During the quarter, the company generated $22.93 million in EBITDA. The liabilities of Supernus Pharmaceuticals Inc. were 840.33 million at the end of its most recent quarter ended June 29, and its total debt was $445.03 million. The value of shareholders’ equity is $54.06 million.
This quick technical analysis looks at Supernus Pharmaceuticals Inc.’s (SUPN) price momentum. With a historical volatility rate of 19.31%, the RSI 9-day stood at 57.18% on 23 November.
With respect to its five-day moving average, the current Supernus Pharmaceuticals Inc. price is up by +3.32% percent or $1.12. At present, SUPN shares trade +0.81% above its 20-day simple moving average and +16.91% percent above its 100-day simple moving average. However, the stock is currently trading approximately +0.61% above its SMA50 and +11.49% above its SMA200.
Stochastic coefficient K was 70.94% and Stochastic coefficient D was 66.91%, while ATR was 0.99. Given the Stochastic reading of 71.92% for the 14-day period, the RSI (14) reading has been calculated as 55.38%. As of today, the MACD Oscillator reading stands at 0.33, while the 14-day reading stands at 0.47.
Supernus Pharmaceuticals Inc. (SUPN) has been rated Overweight by analysts. According to 0 brokerage firms, SUPN is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Supernus Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $40.00, the current consensus forecast for the stock is $33.00 – $43.00. Based on these forecasts, analysts predict Supernus Pharmaceuticals Inc. (SUPN) will achieve an average price target of $38.67.